Commercial Kardigan targets IPO to support cardiology pipeline progression Pharmaceutical TechnologyKardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline.CardiovascularRead full story pharminent May 27, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology Kardigan plans to use the IPO funds to push its three in-licensed, mid-to-late-stage heart health therapies down the clinical pipeline. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA delays verdict on AZ breast cancer drugNext: Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss Related Stories Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026 Commercial Tryngolza charts blockbuster course after FDA’s hypertriglyceridemia approval pharminent June 26, 2026 Commercial Lilly launches its LillyDirect sales channel in the UK pharminent June 25, 2026
